Clopidogrel poor metabolizers may need alternative to standard regimen

Thompson, Cheryl A.
May 2010
American Journal of Health-System Pharmacy;5/15/2010, Vol. 67 Issue 10, p779
Academic Journal
The article offers information on a study related to clopidogrel containing poor metabolizer by specialists Kathryn M. Momary and Sarah A. Spinler. It reports that clopidogrel's active metabolite inhibits platelet aggregation. It mentions that the poor metabolizers had a higher risk for nonfatal myocardial infarction, stroke, or death.


Related Articles

  • Prasugrel Versus High Dose Clopidogrel to Overcome Early High on Clopidogrel Platelet Reactivity in Patients with ST Elevation Myocardial Infarction. Alexopoulos, D.; Theodoropoulos, K.; Stavrou, E.; Xanthopoulou, I.; Kassimis, G.; Tsigkas, G.; Damelou, A.; Davlouros, P.; Hahalis, G.; Athanassiadou, A. // Cardiovascular Drugs & Therapy;Oct2012, Vol. 26 Issue 5, p393 

    Objective: There is a paucity of data regarding the early effectiveness of the proposed 600 mg clopidogrel loading dose (LD) on platelet reactivity (PR) in ST elevation myocardial infarction (STEMI) patients. If high on-treatment platelet reactivity (HTPR) is present, prasugrel reloading and...

  • Bivalirudin plus loading dose of cilostazol-based triple-antiplatelet in treatment of non-ST-elevation myocardial infarction following percutaneous coronary intervention. Mei Wang; Guoru Zhang; Yaling Wang; Kun Zhou; Tao Liu; Yang Zhang; Anjun Guo; Yu An; Xiaodan Zhang; Yongjun Li; Wang, Mei; Zhang, Guoru; Wang, Yaling; Zhou, Kun; Liu, Tao; Zhang, Yang; Guo, Anjun; An, Yu; Zhang, Xiaodan; Li, Yongjun // Therapeutics & Clinical Risk Management;Sep2015, Vol. 11, p1469 

    Objective: To study the effect of bivalirudin plus loading dose of cilostazol-based triple-antiplatelet therapy strategy in patients undergoing percutaneous coronary intervention (PCI).Methods: One hundred and fifty-three patients with non-ST-segment elevation...

  • Significance of antiplatelet therapy in emergency myocardial infarction treatment. Komosa, Anna; Lesiak, Maciej; Siniawski, Andrzej; Mularek-Kubzdela, Tatiana; Grajek, Stefan // Advances in Interventional Cardiology;2014, Vol. 10 Issue 1, p32 

    Antiplatelet drugs play a crucial role in the treatment of patients with myocardial infarction, particularly in association with percutaneous coronary intervention. Their main advantage is the reduction of adverse ischemic incidents and the major disadvantage is the increase in the frequency of...

  • Effects of New Antiplatelet Agents and Aldosterone Receptor Antagonists on Mortality in Patients with Myocardial Infarction. Eyuboglu, Mehmet // Cardiovascular Drugs & Therapy;Oct2015, Vol. 29 Issue 5, p495 

    A letter to the editor is presented in response to the article "Effects of New Antiplatelet Agents and Aldosterone Receptor Antagonists on Mortality in Patients With Myocardial Infarction," that was published in the previous issue.

  • clopidogrel.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p469 

    A definition of the medical term "clopidogrel," which refers to a platelet aggregation inhibitor intended for reducing atherosclerotic events, is presented.

  • Clopidogrel in Secondary Ischemic Stroke Prevention. Belv�s, Robert; Pagonabarraga, Javier; Santamar�a, Amparo; Kulisevsky, Jaime // Recent Patents on Cardiovascular Drug Discovery;Jun2008, Vol. 3 Issue 2, p119 

    The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD). Clopidogrel showed a similar efficacy and...

  • Very Late Stent Thrombosis of Sirolimus-eluting Stent 59 Months After Implantation: A First Report from The Middle-East and Review of Literature. Panduranga, Prashanth; Al-Mukhaini, Mohammed // Heart Views;Jan-Mar2011, Vol. 12 Issue 1, p22 

    Very late stent thrombosis occurs more frequently with drug-eluting stents and tends to occur despite dual antiplatelet therapy or after long periods of clopidogrel discontinuation. Stent thrombosis commonly presents with myocardial infarction or death. We report a 41-year-old Arab male with...

  • Is it safe to prolong dual antiplatelet therapy after DES implantation beyond 12 months? Vintila, Vlad // Maedica - a Journal of Clinical Medicine;2010, Vol. 5 Issue 1, p71 

    The article presents a study on the prolonging dual antiplatelet therapy after drug eluting stent (DES) implantation. The study presents two trials addressing the issue of prolongation of the dual antiplatelet therapy (Aspirin plus Clopidogrel) and uses Metaanalysis Techniques to gather data....

  • SHORT CUTS. Fister, Kristina // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/5/2009, Vol. 339 Issue 7720, p536 

    This section discusses various health-related studies published in different journals. A study published in the "New England Journal of Medicine" estimated the cumulative doses of radiation received by patients in the U.S. during imaging procedures. Another study published in the same journal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics